Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB
- PMID: 11118032
Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB
Abstract
To investigate the role of the transcription factor nuclear factor kappaB (NFkappaB) in tumor metastasis, we generated a murine lung alveolar carcinoma cell line (Line 1) defective in NFkappaB-signaling by retroviral delivery of a dominant negative inhibitor of NFkappaB. The NFkappaB signal blockade resulted in the down-regulation of prometastatic matrix metalloproteinase 9, a urokinase-like plasminogen activator, and heparanase and reciprocal up-regulation of antimetastatic tissue inhibitors of matrix metalloproteinases 1 and 2 and plasminogen activator inhibitor 2. NFkappaB signal blockade did not affect tumor cell proliferation in vitro or in vivo but prevented intravasation of tumor cells in an in vivo chick chorioallantoic membrane model of metastasis as well as spontaneous metastasis in a murine model. These findings suggest that NFkappaB plays a central and specific role in the regulation of tumor metastasis and may be an important therapeutic target for development of antimetastatic cancer treatments.
Similar articles
-
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4140-9. doi: 10.1158/1078-0432.CCR-03-0574. Clin Cancer Res. 2004. PMID: 15217951
-
Function of nuclear factor kappaB in pancreatic cancer metastasis.Clin Cancer Res. 2003 Jan;9(1):346-54. Clin Cancer Res. 2003. PMID: 12538487
-
Molecular events involved in the increased expression of matrix metalloproteinase-9 by T lymphocytes of mammary tumor-bearing mice.Int J Mol Med. 2008 Jan;21(1):125-34. Int J Mol Med. 2008. PMID: 18097625
-
Genetic control of the metastatic phenotype.Semin Cancer Biol. 1991 Apr;2(2):105-10. Semin Cancer Biol. 1991. PMID: 1912520 Review.
-
NFκB/p53 crosstalk-a promising new therapeutic target.Biochim Biophys Acta. 2011 Jan;1815(1):90-103. doi: 10.1016/j.bbcan.2010.10.003. Epub 2010 Oct 15. Biochim Biophys Acta. 2011. PMID: 20951769 Review.
Cited by
-
MyD88 signaling pathways: role in breast cancer.Front Oncol. 2024 Jan 29;14:1336696. doi: 10.3389/fonc.2024.1336696. eCollection 2024. Front Oncol. 2024. PMID: 38347830 Free PMC article. Review.
-
Mammalian heparanase: what is the message?J Cell Mol Med. 2007 May-Jun;11(3):427-52. doi: 10.1111/j.1582-4934.2007.00039.x. J Cell Mol Med. 2007. PMID: 17635638 Free PMC article. Review.
-
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression.Neoplasia. 2004 Jul-Aug;6(4):390-400. doi: 10.1593/neo.04112. Neoplasia. 2004. PMID: 15256061 Free PMC article.
-
Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.Tumour Biol. 2016 Aug;37(8):11469-77. doi: 10.1007/s13277-016-5004-3. Epub 2016 Mar 24. Tumour Biol. 2016. PMID: 27012551
-
Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression.Nat Commun. 2016 Nov 25;7:13561. doi: 10.1038/ncomms13561. Nat Commun. 2016. PMID: 27886186 Free PMC article.